AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
By Michael Susin
AstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals.
The British-Swedish pharma giant on Tuesday said the phase three trial for the use of Truqap plus chemotherapy showed that the treatment didn't meet the dual primary endpoints of improvement in overall survival when compared with the chemotherapy plus placebo. The study was applied in patients with inoperable or metastatic triple-negative breast cancer.
"Despite modest advances, triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known actionable biomarker targets, and chemotherapy-based regimens continue to be the mainstay of treatment. While the CAPItello-290 trial results have not shown what we hoped, they provide important information to further understand this aggressive form of breast cancer where patients are in urgent need of new treatments," said Peter Schmid, the trial's main investigator.
However, the company added that Truqap is currently being evaluated in late stage trials for the treatment of breast cancer and prostate cancer in combination with established treatments.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
June 18, 2024 02:36 ET (06:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations